<DOC>
	<DOCNO>NCT00001499</DOCNO>
	<brief_summary>2-Drug Combination Chemotherapy Followed Radiotherapy . Paclitaxel , TAX , NSC-125973 ; Cisplatin , CDDP , NSC-119875 ; follow chest irradiation use 4-15 MV photon .</brief_summary>
	<brief_title>Phase II Neoadjuvant Trial Continuous Infusion Paclitaxel Plus Cisplatin Followed Chest Radiotherapy Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This Phase II study paclitaxel administer 96-hour ( 4 day ) continuous infusion bolus cisplatin follow chest radiotherapy previously untreated patient stage III non-small cell lung cancer ( NSCLC ) . The non-small cell lung cancer tissue obtain prior start treatment study mutation p53 gene . The goal phase II study determine response rate 4 cycle infusional paclitaxel bolus cisplatin patient stage III NSCLC . The response assess follow completion 6000 cGy chest radiotherapy patient follow survival . The relationship presence absence p53 mutation sensitivity patient 's tumor paclitaxel plus cisplatin chest radiation study . In addition , plasma level paclitaxel measure , vitro paclitaxel chemosensitivity tumor cell determine many patient possible . This allow study relationship p53 status , vitro drug sensitivity , achievable plasma concentration paclitaxel , patient ' response therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer follow histology : Squamous cell carcinoma , Adenocarcinoma , Large cell carcinoma , No mixed small/nonsmall cell carcinoma predominant small cell component . Unresectable stage IIIA/B disease confine thorax include : Microscopic disease involvement follow attempt surgery limited anatomic area correspond stage III disease ( N23 , T34 ) . Surgically treated stage I/II disease histologic cytologic proof relapse limit anatomic area correspond stage III disease ( N23 , T34 ) . T3 , N0 tumor extend directly chest wall consider resectable eligible . No stage IIIB disease pleural effusion visible chest xray unless relate previous thoracotomy . No typical carcinoid mesothelioma . Measurable disease prefer require . PRIOR/CONCURRENT THERAPY : No prior chemotherapy thoracic radiotherapy . PATIENT CHARACTERISTICS : Age : 18 . Performance status : ECOG 02 . Hematopoietic : AGC great 2,000 . Platelets great 100,000 . Hepatic : Bilirubin great 1.5 mg/dL . Renal : Creatinine great 1.5 mg/dL . Cardiovascular : No symptomatic heart disease include : Less fully compensate congestive cardiac failure , Significant arrhythmias e.g . : Greater firstdegree heart block , Uncontrolled symptomatic atrial dysrhythmia except sinus , bradycardia sustain ventricular tachycardia , Myocardial infarction within 3 month . Pulmonary : No major uncontrolled active infection ( unless due obstruct bronchus ) . OTHER : No major active psychiatric problem require hospitalization psychotropic medication phenothiazine . No prior second malignancy within 5 year except : nonmelanomatous skin cancer , In situ carcinoma cervix . No pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2000</verification_date>
	<keyword>Carcinoma</keyword>
	<keyword>Combination Chemotherapy</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Infusion</keyword>
	<keyword>Intravenous</keyword>
	<keyword>Lung Neoplasm</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>